<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59085">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336815</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-012</org_study_id>
    <nct_id>NCT02336815</nct_id>
  </id_info>
  <brief_title>Selinexor Treatment of Refractory Myeloma</brief_title>
  <acronym>STORM</acronym>
  <official_title>A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low- Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor and an Anti-CD38 mAb</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus
      dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with
      penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus
      dexamethasone 20 mg (Sd), both dosed twice weekly in each four-week cycle, in patients with
      MM previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and an
      anti-CD38 monoclonal antibody (mAb) and refractory to prior treatment with glucocorticoids,
      an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 mAb.

      This study consists of two parts:

        -  Part 1 enrolled patients with both quad-refractory MM and penta-refractory MM.

        -  Part 2 will enroll patients with penta-refractory MM only.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>5-7 months</time_frame>
    <description>Achievement of sCR, CR, VGPR, or PR for the overall evaluable population with supportive data provided by DOR (duration of response).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>5-7 months</time_frame>
    <description>The duration of time measured from when measurement criteria for response were first met until the date of first recurrence, PD or death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical Benefit Rate (CBR = sCR + CR + PR + Minor Response [MR]), and duration of CBR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Selinexor &amp; Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selinexor 80 mg (45 mg/m2 BSA) plus low-dose Dexamethasone (20 mg), both twice weekly by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)</description>
    <arm_group_label>Selinexor &amp; Dexamethasone</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20 mg will be given with each dose of Selinexor.</description>
    <arm_group_label>Selinexor &amp; Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Measurable MM based on modified IMWG guidelines. Defined by at least one of the following:

          1. Serum M-protein ≥ 0.5 g/dL by serum electrophoresis (SPEP) or for IgA myeloma, by
             quantitative IgA

          2. Urinary M-protein excretion ≥ 200 mg/24 hours

          3. Free Light Chain (FLC) ≥ 100 mg/L, provided that the FLC ratio is abnormal

          4. If serum protein electrophoresis is felt to be unreliable for routine M-protein
             measurement, then quantitative Ig levels by nephelometry or turbidimetry are
             acceptable

               -  Must have previously received ≥ 3 anti-MM regimens including: an alkylating
                  agent, lenalidomide, pomalidomide, bortezomib, carfilzomib, either daratumumab
                  or isatuximab, and a glucocorticoid. There is no upper limit on the number of
                  prior therapies provided that all other inclusion/exclusion criteria are met.

               -  MM refractory to previous treatment with one or more glucocorticoids, parenteral
                  PI (i.e., bortezomib and/or carfilzomib), IMiD (i.e., lenalidomide and/or
                  pomalidomide), and antiCD38 mAb (i.e., either daratumumab or isatuximab).
                  Refractory is defined as ≤ 25% response to therapy, or progression during
                  therapy or progression within 60 days after completion of therapy.

        Exclusion Criteria:

          -  Active smoldering MM.

          -  Active plasma cell leukemia.

          -  Documented systemic amyloid light chain amyloidosis.

          -  Active CNS MM.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <email>mkauffman@karypharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, PhD</last_name>
    <email>sshacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciano Costa, MD</last_name>
      <phone>800-822-8816</phone>
    </contact>
    <investigator>
      <last_name>Luciano Costa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic (AZ)</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Stewart, MD</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Keith Stewart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jonnsson Comprehensive Cancer Center / University of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Schiller, MD, PhD</last_name>
      <phone>888-798-0719</phone>
    </contact>
    <investigator>
      <last_name>Gary Schiller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Lynn Parker, MD</last_name>
      <phone>203-688-4242</phone>
    </contact>
    <investigator>
      <last_name>Terry Lynn Parker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sylvester, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Hoffman, MD</last_name>
      <phone>305-243-1000</phone>
    </contact>
    <contact_backup>
      <phone>800-545-2292</phone>
    </contact_backup>
    <investigator>
      <last_name>James Hoffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachid Baz, MD</last_name>
      <phone>888-663-3488</phone>
    </contact>
    <investigator>
      <last_name>Rachid Baz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University / Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajay Nooka, MD</last_name>
      <phone>404-778-1868</phone>
    </contact>
    <investigator>
      <last_name>Ajay Nooka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Jakubowiak, MD</last_name>
      <phone>888-824-0200</phone>
    </contact>
    <investigator>
      <last_name>Andrzej Jakubowiak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IU Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafat Abonour, MD</last_name>
      <phone>888-600-4822</phone>
    </contact>
    <investigator>
      <last_name>Rafat Abonour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Huff, MD</last_name>
      <phone>410-955-8804</phone>
    </contact>
    <contact_backup>
      <phone>800-422-6237</phone>
    </contact_backup>
    <investigator>
      <last_name>Carol Huff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ray Comenzo, MD</last_name>
      <phone>617-636-6033</phone>
    </contact>
    <investigator>
      <last_name>Ray Comenzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Yee, MD</last_name>
      <phone>877-789-6100</phone>
    </contact>
    <investigator>
      <last_name>Andrew Yee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Schlossman, MD</last_name>
      <phone>617-632-3823</phone>
    </contact>
    <investigator>
      <last_name>Robert Schlossman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Cole, MD</last_name>
      <phone>877-536-4243</phone>
      <email>UMClinicalStudies@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Cole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Divay Bhutani, MD</last_name>
      <phone>800-527-6266</phone>
      <email>info@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Divay Bhutani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Dingli, MD</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>David Dingli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WUSTL - Washington University in St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravi Vij, MD</last_name>
      <phone>866-867-3627</phone>
    </contact>
    <investigator>
      <last_name>Ravi Vij, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center / John Therurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josh Richter, MD</last_name>
      <phone>551-996-5834</phone>
      <email>JTCCResearch@hackensackUMC.org</email>
    </contact>
    <investigator>
      <last_name>Josh Richter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Hospital</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kaminetzky, MD</last_name>
      <phone>212-263-4432</phone>
    </contact>
    <investigator>
      <last_name>David Kaminetzky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai NYC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sundar Jagannath, MD</last_name>
      <phone>212-241-6500</phone>
    </contact>
    <contact_backup>
      <phone>212-590-3300</phone>
    </contact_backup>
    <investigator>
      <last_name>Sundar Jagannath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Lentzsch, MD</last_name>
      <phone>212-305-5065</phone>
      <email>CTOInformation@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Suzanne Lentzsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Vogl, MD</last_name>
      <phone>800-789-7366</phone>
    </contact>
    <investigator>
      <last_name>Dan Vogl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Cornell, MD</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Robert Cornell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246-2088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Levy, MD</last_name>
    </contact>
    <contact_backup>
      <phone>214-370-1000</phone>
    </contact_backup>
    <investigator>
      <last_name>Moshe Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Bensinger, MD</last_name>
      <phone>855-922-6237</phone>
    </contact>
    <investigator>
      <last_name>William Bensinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>January 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>KPT-330</keyword>
  <keyword>Selinexor</keyword>
  <keyword>Refractory</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>STORM</keyword>
  <keyword>CD38</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
